Migraine and functional impairment

CNS Drugs

Volumn 23, Issue 12, 2009, Pages 1039-1045

  Brandes, Jan Lewis ^a  

^a Nashville Neuroscience Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYSERGIDE; PROPRANOLOL; TIMOLOL; TOPIRAMATE; VALPROATE SEMISODIUM;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ANOREXIA; BRADYCARDIA; CLINICAL ASSESSMENT TOOL; CLINICAL RESEARCH; CLINICAL TRIAL; COLD LIMB; DAILY LIFE ACTIVITY; DELAYED DRUG RELEASE; DIARRHEA; DISABILITY SEVERITY; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE ESCALATION; DYSPEPSIA; FAMILY INTERACTION; FAMILY RELATION; FATIGUE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; GENERAL PRACTITIONER; HUMAN; INFECTION; JOB PERFORMANCE; MENTAL CONCENTRATION; MIGRAINE; NAUSEA; OPEN ENDED QUESTIONNAIRE; PARESTHESIA; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SIDE EFFECT; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOMNOLENCE; STRESS FRACTURE; SUSTAINED DRUG RELEASE; TRANSFORMED MIGRAINE; VOMITING; WEIGHT GAIN; WORK CAPACITY;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; HUMANS; MIGRAINE DISORDERS; PHYSICIANS, FAMILY; PRIMARY HEALTH CARE; QUALITY OF LIFE;

EID: 71449086571     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11530030-000000000-00000     Document Type: Review

References (50)

1. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6: 429-440
2. Dowson A, Jagger S. The UK Migraine Patient Survey: quality of life and treatment. Curr Med Res Opin 1999; 15: 241-253
3. Dahlof CGH, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31-36
4. Hahn SR, Lipton RB, Sheftell FD, et al. Healthcare provider-patient communication and migraine assessment: results of the American Migraine Communication Study (AMCS) phase II. Curr Med Res Opin 2008; 24: 1711-1718
5. Lipton RB, Bigal ME, Diamond M, et al., American Migraine Prevalence and Prevention (AMPP) Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-349
6. Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs 2002; 16 Suppl. 1: 13-18
7. Breslau J, Davis GC. Migraine, physical health and psy-chiatric disorder: a prospective epidemiologic study in young adults. J Psychiat Res 1993; 27: 211-221
8. Dueland AN, Leira R, Burke TA, et al. The impact of migraine on work, family, and leisure among young women: a multinational study. Curr Med Res Opin 2004; 20: 1595-1604
9. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29-35
10. Hawkins K, Wang S, Rupnow MFT. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007; 49: 368-374
11. Bussone G, Usai S, Grazzi L, et al. Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 2004; 25 Suppl. 3: S105-7
12. Lipton RB, Bigal ME, Kolodner K, et al. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia 2003; 23: 429-440
13. Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs: a nation-wide population-based survey in Sweden. Cephalagia 2004; 24: 455-465
14. Asmundson GJG, Norton PJ, Veloso F. Anxiety, sensitivity and fear of pain in patients with recurring headaches. Behav Res Ther 1999; 37: 703-713
15. Freitag FG. The cycle of migraine: patients' quality of life during and between migraine attacks. Clin Ther 2007; 29: 939-949
16. Brandes JL. The migraine cycle: patient burden of migraine during and between migraine attacks. Headache 2008; 48: 430-441
17. Thomas K, Harvey D. New survey reveals worrying between attacks can extend suffering for migraineurs, 2006 Jun 8 [media release online]. Available from URL: http://www. orthomcneilneurologics.com/ortho-mcneilneurologics/pages/ news-release-060806-1.jsp [Accessed 2009 Nov 2]
18. Lipton RB, Stewart WF, Sawyer J, et al. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001; 41: 854-861 (Pubitemid 33043148)
19. Pryse-Phillips W. Evaluating migraine disability: the head-ache impact test instrument in context. Can J Neurol Sci 2002; 29 Suppl. 2: 11-15
20. Jacobson GP, Ramadan NM, Norris L, et al. Headache Disability Inventory (HDI): short-term test-retest reliability and spouse perceptions. Headache 1995; 35: 534-549
21. Dahlof CG. Measuring disability and quality of life in mi-graine. Drugs Today 2003; 39 Suppl. D: 17-23
22. Revicki DA. Health related quality of life in the evaluation of medical therapy for chronic illness. J Fam Pract 1989; 29: 377-380
23. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
24. Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache 2000; 40: 204-215
25. Buse DC, Bigal ME, Rupnow MFT, et al. The Migraine Interictal Burden Scale (MIBS): results of a population-based validation study [abstract no. S05.003]. 59th Annual Meeting of the American Academy of Neurology; 2007 Apr 28-May 5; Boston (MA)
26. Dueland AN, Leira R, Cabelli ST. The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Curr Med Res Opin 2005; 21: 1297-1305
27. Martin LR, Jahng KH, Golin CE, et al. Physician facilita-tion of patient involvement in care: correspondence between patient and observer reports. Behav Med 2003; 28: 159-164
28. Lipton RB, Hahn SR, Cady RK, et al. In-office discussions of migraine: results from the American Migraine Communication Study. J Gen Intern Med 2008; 23: 1145-1151
29. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia 2004; 24 Suppl. 1: 1-15
30. Ramadan NM. Migraine headache prophylaxis: current opinions and advances on the horizon. Curr Neurol Neuro-sci Rep 2006; 6: 95-99
31. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000; 54: 1553
32. Silberstein SD. 2000. Practice Parameter: Evidence-based Guidelines for Migraine Headache (An Evidence-based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. St. Paul (MN): American Academy of Neurology
33. Brandes JL. Practical use of topiramate for migraine pre-vention. Headache 2005; 45 Suppl. 1: S66-73
34. Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL. Migraine: current therapeutic targets and future avenues. Curr Vasc Pharmacology 2006; 4: 117-128
35. Linde K, Rossnagel K. Propranolol for migraine prophy-laxis. Cochrane Database Syst Rev 2004; (2): CD003225
36. Ramadan M, Silberstein SD, Freitag FB, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [online]. Available from URL: http://www.aan.com/ profes sionals/practice/pdfs/gl0090.pdf [Accessed 2009 Sep 17]
37. Loder E, Biondi D. General principles of migraine man-agement: the changing role of prevention. Headache 2005; 45 Suppl. 1: S33-47
38. Blocadren (timolol maleate) tablets label [online]. Available from URL: http://www.merck.com/product/usa/pi-circulars/ b/blocadren/blocadren-pi.pdf [Accessed, 2008 Mar 17]
39. Inderal (propranolol hydrochloride) tablets label [online]. Available from URL: http://www.wyeth.com/content/Show Labeling.asp?id=106 [Accessed, 2008 Mar 17]
40. Brandes JL, Saper JR, Diamond M, et al., MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-973
41. Silberstein SD, Neto W, Scmitt J, et al., MIGR-001 Study Group. Topiramate in migraine prevention: results from a large controlled trial. Arch Neurol 2004; 61: 490-495 (Pubitemid 38923736)
42. Silberstein SD, Lipton RB, Dodick DW, et al., Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-180
43. Silberstein S, Loder E, Forde G, et al. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin 2006; 22: 1021-1029
44. Brandes JL, Kudrow DB, Rothrock JF, et al. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc 2006; 81: 1311-1319
45. Diamond M, Dahlof C, Papadopoulos G, et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005; 45: 1023-1030
46. Dodick DW, Silberstein SD, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007; 47: 1398-1408
47. Topamax® (topiramate) tablets label [online]. Available from URL: http://www.topamax.com/topamax/tools-resources-prescribing-information.html [Accessed, 2008 Mar 17]
48. Mathew NT, Saper JR, Silberstein SD, et al. Migraine pro-phylaxis with divalproex. Arch Neurol 1995; 52: 281-286
49. Freitag FG, Collins SD, Carlson HA, et al., Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652-1659
50. Depakote (divalproex sodium) delayed-release tablets label [online]. Available from URL: http://www.depakoteer.com/ depakoteer/patient/migraines/ prescribing-information.jsp [Accessed, 2008 Mar 17]